查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866638

间质干细胞：全球市占率及排名、总收入及需求预测（2025-2031年）

Mesenchymal Stem Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 128 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球间质干细胞市场预计在 2024 年达到 12.45 亿美元，预计到 2031 年将达到 25.42 亿美元，在 2025 年至 2031 年的预测期内，复合年增长率将达到 10.6%。

间质干细胞（MSCs）是一种来自多种组织的多功能能干细胞，包括骨髓、脐带、脂肪组织和胎盘。它们具有强大的自我更新和多系分化潜能，能够分化成成骨细胞、软骨细胞、脂肪细胞和其他间质来源细胞。 MSCs具有低免疫抗原性、免疫调节活性和强大的细胞激素分泌能力，使其成为再生医学、免疫疗法和抗发炎治疗的重要研究对象。随着细胞培养技术、无血清培养基和符合GMP规范的生产过程的进步，MSCs正从临床前研究走向临床应用，并被广泛应用于整形外科疾病、心血管疾病、自体免疫疾病、肿瘤学和组织工程等领域。间质干细胞（MSC）产业涵盖上游工程细胞获取、大规模培养、冷冻保存、物流和治疗产品开发，使MSC成为全球细胞和基因治疗（CGT）市场的基础，也是精准医疗的关键驱动力。这引起了全球投资者和监管机构的广泛关注。

间质干细胞（MSC）产业正进入加速成长阶段，这主要得益于全球细胞和基因治疗研发的快速发展、人口老化带来的医疗保健需求成长以及对再生医学的支持性政策。根据公开的年度报告，正在进行的MSC临床试验数量持续增加，仅2024年，美国和中国就註册了300多项试验，涵盖神经系统疾病、代谢性疾病和自体免疫疾病。世界各国政府正大力投资创新，并透过支持符合GMP标准的生产设施和品质标准化来降低技术壁垒。跨国製药公司与区域性CDMO（合约研发生产机构）之间的频繁合作，正在促进工业化生产和快速市场渗透。随着来自亚洲和中东的投资不断增加，MSC有望成为全球精准医疗和个人化医疗发展的重要策略重点。

儘管间质干细胞（MSC）产业发展迅速，但仍面临许多挑战，例如细胞获取复杂、大规模生产困难、临床通讯协定不一致以及监管要求存在区域差异。许多公司缺乏成熟的製程优化和批次间一致性经验，导致高成本且商业化週期长。智慧财产权壁垒、跨境临床审批以及全球监管的复杂性进一步增加了进入门槛，尤其对中小企业而言更是如此。市场不确定性，例如资本市场波动和医疗报销政策，也是风险因素。如何在严格的品质标准、成本效益和价格可负担之间取得平衡，对于塑造竞争格​​局至关重要。

市场需求正迅速从基础研究转向商业性临床应用。随着免疫疗法、组织工程和个人化医疗的发展，间质干细胞（MSC）的应用范围不断扩大，涵盖心血管修復、软骨再生、自体免疫疾病管理、抗衰老龄化疗法和医学美容等领域。与mRNA和基因编辑技术的融合，为高品质、客製化的MSC产品创造了巨大的发展机会。企业和研究机构正在加速推动自动化和数位化流程控制，以提高产品一致性并降低成本。人口老化、慢性病高发生率以及相关政策的支持，将使MSC在未来五年内成为全球细胞治疗市场的核心成长引擎。

本报告旨在对全球间间质干细胞市场进行全面分析，重点关注总收入、市场份额和主要企业的排名，并按地区/国家、类型和应用进行分析。

本报告以销售收入为指标，间质干细胞市场规模、估算和预测进行了呈现，以2024年为基准年，并包含了2020年至2031年的历史数据和预测数据。定量和定性分析将帮助读者制定业务/成长策略、评估市场竞争、分析自身在当前市场中的地位，并就间质干细胞做出明智的商业决策。

市场区隔

公司

  • CellResearch
  • StemCord
  • Cytopeutics
  • CryoCord
  • Cell Malaysia
  • Bangkok Stem Cell
  • Vinmec Stem Cell Institute
  • ProSTEM
  • Cryoviva
  • StemCells21
  • Lonza
  • Thermo Fisher Scientific
  • PromoCell
  • Stemcell Technologies
  • Bio-Techne
  • ATCC
  • Merck

按类型分類的细分市场

  • 脐带间质干细胞
  • 骨髓间质干细胞
  • 胎盘来源的间质干细胞
  • 其他的

应用领域

  • 调查
  • 疾病治疗
  • 美容与抗衰老
  • 保持

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Mesenchymal Stem Cells was estimated to be worth US$ 1245 million in 2024 and is forecast to a readjusted size of US$ 2542 million by 2031 with a CAGR of 10.6% during the forecast period 2025-2031.

Mesenchymal Stem Cells (MSCs) are multipotent stem cells derived from various tissues such as bone marrow, umbilical cord, adipose tissue, and placenta. They possess strong self-renewal and multilineage differentiation capabilities, enabling them to differentiate into osteoblasts, chondrocytes, adipocytes, and other mesenchymal-origin cells. MSCs are characterized by low immunogenicity, immunomodulatory effects, and robust cytokine secretion, making them a key focus in regenerative medicine, immune therapy, and anti-inflammatory treatment. With advancements in cell culture techniques, serum-free media, and GMP-compliant manufacturing, MSCs are transitioning from preclinical research to clinical applications, finding broad use in orthopedic disorders, cardiovascular diseases, autoimmune conditions, oncology, and tissue engineering. The MSC industry spans upstream cell sourcing, large-scale expansion, cryopreservation, logistics, and therapeutic product development, positioning MSCs as a cornerstone of the global cell and gene therapy (CGT) market and a critical driver of precision medicine, drawing strong attention from investors and regulatory authorities worldwide.

The mesenchymal stem cell (MSC) industry is entering a phase of accelerated growth, driven by the global boom in cell and gene therapy R&D, rising healthcare needs of aging populations, and supportive regenerative medicine policies. According to public annual reports, the number of ongoing MSC clinical trials continues to grow, with over 300 trials registered in the U.S. and China in 2024 alone, covering neurological, metabolic, and autoimmune disorders. Governments are investing heavily in innovation, supporting GMP-compliant manufacturing facilities and quality standardization, reducing technical barriers. Frequent collaborations between multinational pharmaceutical companies and regional CDMOs are facilitating industrial-scale production and rapid market penetration. With increasing investments from Asia and the Middle East, MSCs are poised to become a strategic focus in global precision and personalized medicine development.

Despite rapid growth, the MSC industry faces challenges such as complex cell sourcing, difficulties in large-scale manufacturing, inconsistent clinical protocols, and varying regulatory requirements across regions. Many companies lack mature experience in process optimization and batch consistency, resulting in high costs and extended commercialization timelines. Intellectual property barriers, cross-border clinical certifications, and global regulatory complexities further increase entry thresholds, particularly for small and mid-sized players. Market uncertainties, including fluctuations in capital markets and healthcare reimbursement policies, also pose risks. Balancing strict quality standards, cost efficiency, and accessible pricing will be critical for shaping the competitive landscape.

Demand is rapidly shifting from basic research to commercial clinical applications. The growth of immunotherapy, tissue engineering, and personalized medicine is expanding MSC use cases, including cardiovascular repair, cartilage regeneration, autoimmune disease management, anti-aging therapies, and medical aesthetics. Emerging integration with mRNA technology and gene editing is creating vast opportunities for premium, customized MSC products. Companies and research institutions are accelerating automation and digital process control to enhance product consistency and reduce costs. The convergence of aging demographics, chronic disease prevalence, and supportive policy frameworks positions MSCs as a central growth engine in the global cell therapy market over the next five years.

This report aims to provide a comprehensive presentation of the global market for Mesenchymal Stem Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mesenchymal Stem Cells by region & country, by Type, and by Application.

The Mesenchymal Stem Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesenchymal Stem Cells.

Market Segmentation

By Company

  • CellResearch
  • StemCord
  • Cytopeutics
  • CryoCord
  • Cell Malaysia
  • Bangkok Stem Cell
  • Vinmec Stem Cell Institute
  • ProSTEM
  • Cryoviva
  • StemCells21
  • Lonza
  • Thermo Fisher Scientific
  • PromoCell
  • Stemcell Technologies
  • Bio-Techne
  • ATCC
  • Merck

Segment by Type

  • Umbilical Cord Derived MSC
  • Bone Marrow Derived MSC
  • Placenta Derived MSC
  • Other

Segment by Application

  • Research
  • Disease Treatment
  • Beauty and Anti-aging
  • Storage

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Mesenchymal Stem Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Mesenchymal Stem Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Mesenchymal Stem Cells in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Mesenchymal Stem Cells Product Introduction
  • 1.2 Global Mesenchymal Stem Cells Market Size Forecast (2020-2031)
  • 1.3 Mesenchymal Stem Cells Market Trends & Drivers
    • 1.3.1 Mesenchymal Stem Cells Industry Trends
    • 1.3.2 Mesenchymal Stem Cells Market Drivers & Opportunity
    • 1.3.3 Mesenchymal Stem Cells Market Challenges
    • 1.3.4 Mesenchymal Stem Cells Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Mesenchymal Stem Cells Players Revenue Ranking (2024)
  • 2.2 Global Mesenchymal Stem Cells Revenue by Company (2020-2025)
  • 2.3 Key Companies Mesenchymal Stem Cells Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Mesenchymal Stem Cells Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Mesenchymal Stem Cells
  • 2.6 Mesenchymal Stem Cells Market Competitive Analysis
    • 2.6.1 Mesenchymal Stem Cells Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Mesenchymal Stem Cells Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cells as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Umbilical Cord Derived MSC
    • 3.1.2 Bone Marrow Derived MSC
    • 3.1.3 Placenta Derived MSC
    • 3.1.4 Other
  • 3.2 Global Mesenchymal Stem Cells Sales Value by Type
    • 3.2.1 Global Mesenchymal Stem Cells Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Mesenchymal Stem Cells Sales Value, by Type (2020-2031)
    • 3.2.3 Global Mesenchymal Stem Cells Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Research
    • 4.1.2 Disease Treatment
    • 4.1.3 Beauty and Anti-aging
    • 4.1.4 Storage
  • 4.2 Global Mesenchymal Stem Cells Sales Value by Application
    • 4.2.1 Global Mesenchymal Stem Cells Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Mesenchymal Stem Cells Sales Value, by Application (2020-2031)
    • 4.2.3 Global Mesenchymal Stem Cells Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Mesenchymal Stem Cells Sales Value by Region
    • 5.1.1 Global Mesenchymal Stem Cells Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Mesenchymal Stem Cells Sales Value by Region (2020-2025)
    • 5.1.3 Global Mesenchymal Stem Cells Sales Value by Region (2026-2031)
    • 5.1.4 Global Mesenchymal Stem Cells Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.2.2 North America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.3.2 Europe Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Mesenchymal Stem Cells Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.5.2 South America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Mesenchymal Stem Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Mesenchymal Stem Cells Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.3.2 United States Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.4.2 Europe Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.5.2 China Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.6.2 Japan Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.7.2 South Korea Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.9.2 India Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 CellResearch
    • 7.1.1 CellResearch Profile
    • 7.1.2 CellResearch Main Business
    • 7.1.3 CellResearch Mesenchymal Stem Cells Products, Services and Solutions
    • 7.1.4 CellResearch Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.1.5 CellResearch Recent Developments
  • 7.2 StemCord
    • 7.2.1 StemCord Profile
    • 7.2.2 StemCord Main Business
    • 7.2.3 StemCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.2.4 StemCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.2.5 StemCord Recent Developments
  • 7.3 Cytopeutics
    • 7.3.1 Cytopeutics Profile
    • 7.3.2 Cytopeutics Main Business
    • 7.3.3 Cytopeutics Mesenchymal Stem Cells Products, Services and Solutions
    • 7.3.4 Cytopeutics Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Cytopeutics Recent Developments
  • 7.4 CryoCord
    • 7.4.1 CryoCord Profile
    • 7.4.2 CryoCord Main Business
    • 7.4.3 CryoCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.4.4 CryoCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.4.5 CryoCord Recent Developments
  • 7.5 Cell Malaysia
    • 7.5.1 Cell Malaysia Profile
    • 7.5.2 Cell Malaysia Main Business
    • 7.5.3 Cell Malaysia Mesenchymal Stem Cells Products, Services and Solutions
    • 7.5.4 Cell Malaysia Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Cell Malaysia Recent Developments
  • 7.6 Bangkok Stem Cell
    • 7.6.1 Bangkok Stem Cell Profile
    • 7.6.2 Bangkok Stem Cell Main Business
    • 7.6.3 Bangkok Stem Cell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.6.4 Bangkok Stem Cell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Bangkok Stem Cell Recent Developments
  • 7.7 Vinmec Stem Cell Institute
    • 7.7.1 Vinmec Stem Cell Institute Profile
    • 7.7.2 Vinmec Stem Cell Institute Main Business
    • 7.7.3 Vinmec Stem Cell Institute Mesenchymal Stem Cells Products, Services and Solutions
    • 7.7.4 Vinmec Stem Cell Institute Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Vinmec Stem Cell Institute Recent Developments
  • 7.8 ProSTEM
    • 7.8.1 ProSTEM Profile
    • 7.8.2 ProSTEM Main Business
    • 7.8.3 ProSTEM Mesenchymal Stem Cells Products, Services and Solutions
    • 7.8.4 ProSTEM Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.8.5 ProSTEM Recent Developments
  • 7.9 Cryoviva
    • 7.9.1 Cryoviva Profile
    • 7.9.2 Cryoviva Main Business
    • 7.9.3 Cryoviva Mesenchymal Stem Cells Products, Services and Solutions
    • 7.9.4 Cryoviva Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Cryoviva Recent Developments
  • 7.10 StemCells21
    • 7.10.1 StemCells21 Profile
    • 7.10.2 StemCells21 Main Business
    • 7.10.3 StemCells21 Mesenchymal Stem Cells Products, Services and Solutions
    • 7.10.4 StemCells21 Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.10.5 StemCells21 Recent Developments
  • 7.11 Lonza
    • 7.11.1 Lonza Profile
    • 7.11.2 Lonza Main Business
    • 7.11.3 Lonza Mesenchymal Stem Cells Products, Services and Solutions
    • 7.11.4 Lonza Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Lonza Recent Developments
  • 7.12 Thermo Fisher Scientific
    • 7.12.1 Thermo Fisher Scientific Profile
    • 7.12.2 Thermo Fisher Scientific Main Business
    • 7.12.3 Thermo Fisher Scientific Mesenchymal Stem Cells Products, Services and Solutions
    • 7.12.4 Thermo Fisher Scientific Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Thermo Fisher Scientific Recent Developments
  • 7.13 PromoCell
    • 7.13.1 PromoCell Profile
    • 7.13.2 PromoCell Main Business
    • 7.13.3 PromoCell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.13.4 PromoCell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.13.5 PromoCell Recent Developments
  • 7.14 Stemcell Technologies
    • 7.14.1 Stemcell Technologies Profile
    • 7.14.2 Stemcell Technologies Main Business
    • 7.14.3 Stemcell Technologies Mesenchymal Stem Cells Products, Services and Solutions
    • 7.14.4 Stemcell Technologies Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Stemcell Technologies Recent Developments
  • 7.15 Bio-Techne
    • 7.15.1 Bio-Techne Profile
    • 7.15.2 Bio-Techne Main Business
    • 7.15.3 Bio-Techne Mesenchymal Stem Cells Products, Services and Solutions
    • 7.15.4 Bio-Techne Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Bio-Techne Recent Developments
  • 7.16 ATCC
    • 7.16.1 ATCC Profile
    • 7.16.2 ATCC Main Business
    • 7.16.3 ATCC Mesenchymal Stem Cells Products, Services and Solutions
    • 7.16.4 ATCC Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.16.5 ATCC Recent Developments
  • 7.17 Merck
    • 7.17.1 Merck Profile
    • 7.17.2 Merck Main Business
    • 7.17.3 Merck Mesenchymal Stem Cells Products, Services and Solutions
    • 7.17.4 Merck Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.17.5 Merck Recent Developments

8 Industry Chain Analysis

  • 8.1 Mesenchymal Stem Cells Industrial Chain
  • 8.2 Mesenchymal Stem Cells Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Mesenchymal Stem Cells Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Mesenchymal Stem Cells Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Mesenchymal Stem Cells Market Trends
  • Table 2. Mesenchymal Stem Cells Market Drivers & Opportunity
  • Table 3. Mesenchymal Stem Cells Market Challenges
  • Table 4. Mesenchymal Stem Cells Market Restraints
  • Table 5. Global Mesenchymal Stem Cells Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Mesenchymal Stem Cells Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Mesenchymal Stem Cells Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Mesenchymal Stem Cells Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Mesenchymal Stem Cells
  • Table 10. Global Mesenchymal Stem Cells Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cells as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Mesenchymal Stem Cells Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Mesenchymal Stem Cells Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Mesenchymal Stem Cells Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Mesenchymal Stem Cells Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Mesenchymal Stem Cells Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Mesenchymal Stem Cells Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Mesenchymal Stem Cells Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Mesenchymal Stem Cells Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Mesenchymal Stem Cells Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Mesenchymal Stem Cells Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Mesenchymal Stem Cells Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Mesenchymal Stem Cells Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Mesenchymal Stem Cells Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Mesenchymal Stem Cells Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Mesenchymal Stem Cells Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Mesenchymal Stem Cells Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Mesenchymal Stem Cells Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Mesenchymal Stem Cells Sales Value, (2026-2031) & (US$ Million)
  • Table 31. CellResearch Basic Information List
  • Table 32. CellResearch Description and Business Overview
  • Table 33. CellResearch Mesenchymal Stem Cells Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Mesenchymal Stem Cells Business of CellResearch (2020-2025)
  • Table 35. CellResearch Recent Developments
  • Table 36. StemCord Basic Information List
  • Table 37. StemCord Description and Business Overview
  • Table 38. StemCord Mesenchymal Stem Cells Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Mesenchymal Stem Cells Business of StemCord (2020-2025)
  • Table 40. StemCord Recent Developments
  • Table 41. Cytopeutics Basic Information List
  • Table 42. Cytopeutics Description and Business Overview
  • Table 43. Cytopeutics Mesenchymal Stem Cells Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cytopeutics (2020-2025)
  • Table 45. Cytopeutics Recent Developments
  • Table 46. CryoCord Basic Information List
  • Table 47. CryoCord Description and Business Overview
  • Table 48. CryoCord Mesenchymal Stem Cells Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Mesenchymal Stem Cells Business of CryoCord (2020-2025)
  • Table 50. CryoCord Recent Developments
  • Table 51. Cell Malaysia Basic Information List
  • Table 52. Cell Malaysia Description and Business Overview
  • Table 53. Cell Malaysia Mesenchymal Stem Cells Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cell Malaysia (2020-2025)
  • Table 55. Cell Malaysia Recent Developments
  • Table 56. Bangkok Stem Cell Basic Information List
  • Table 57. Bangkok Stem Cell Description and Business Overview
  • Table 58. Bangkok Stem Cell Mesenchymal Stem Cells Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Bangkok Stem Cell (2020-2025)
  • Table 60. Bangkok Stem Cell Recent Developments
  • Table 61. Vinmec Stem Cell Institute Basic Information List
  • Table 62. Vinmec Stem Cell Institute Description and Business Overview
  • Table 63. Vinmec Stem Cell Institute Mesenchymal Stem Cells Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Vinmec Stem Cell Institute (2020-2025)
  • Table 65. Vinmec Stem Cell Institute Recent Developments
  • Table 66. ProSTEM Basic Information List
  • Table 67. ProSTEM Description and Business Overview
  • Table 68. ProSTEM Mesenchymal Stem Cells Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Mesenchymal Stem Cells Business of ProSTEM (2020-2025)
  • Table 70. ProSTEM Recent Developments
  • Table 71. Cryoviva Basic Information List
  • Table 72. Cryoviva Description and Business Overview
  • Table 73. Cryoviva Mesenchymal Stem Cells Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cryoviva (2020-2025)
  • Table 75. Cryoviva Recent Developments
  • Table 76. StemCells21 Basic Information List
  • Table 77. StemCells21 Description and Business Overview
  • Table 78. StemCells21 Mesenchymal Stem Cells Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Mesenchymal Stem Cells Business of StemCells21 (2020-2025)
  • Table 80. StemCells21 Recent Developments
  • Table 81. Lonza Basic Information List
  • Table 82. Lonza Description and Business Overview
  • Table 83. Lonza Mesenchymal Stem Cells Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Lonza (2020-2025)
  • Table 85. Lonza Recent Developments
  • Table 86. Thermo Fisher Scientific Basic Information List
  • Table 87. Thermo Fisher Scientific Description and Business Overview
  • Table 88. Thermo Fisher Scientific Mesenchymal Stem Cells Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Thermo Fisher Scientific (2020-2025)
  • Table 90. Thermo Fisher Scientific Recent Developments
  • Table 91. PromoCell Basic Information List
  • Table 92. PromoCell Description and Business Overview
  • Table 93. PromoCell Mesenchymal Stem Cells Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Mesenchymal Stem Cells Business of PromoCell (2020-2025)
  • Table 95. PromoCell Recent Developments
  • Table 96. Stemcell Technologies Basic Information List
  • Table 97. Stemcell Technologies Description and Business Overview
  • Table 98. Stemcell Technologies Mesenchymal Stem Cells Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Stemcell Technologies (2020-2025)
  • Table 100. Stemcell Technologies Recent Developments
  • Table 101. Bio-Techne Basic Information List
  • Table 102. Bio-Techne Description and Business Overview
  • Table 103. Bio-Techne Mesenchymal Stem Cells Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Bio-Techne (2020-2025)
  • Table 105. Bio-Techne Recent Developments
  • Table 106. ATCC Basic Information List
  • Table 107. ATCC Description and Business Overview
  • Table 108. ATCC Mesenchymal Stem Cells Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Mesenchymal Stem Cells Business of ATCC (2020-2025)
  • Table 110. ATCC Recent Developments
  • Table 111. Merck Basic Information List
  • Table 112. Merck Description and Business Overview
  • Table 113. Merck Mesenchymal Stem Cells Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Merck (2020-2025)
  • Table 115. Merck Recent Developments
  • Table 116. Key Raw Materials Lists
  • Table 117. Raw Materials Key Suppliers Lists
  • Table 118. Mesenchymal Stem Cells Downstream Customers
  • Table 119. Mesenchymal Stem Cells Distributors List
  • Table 120. Research Programs/Design for This Report
  • Table 121. Key Data Information from Secondary Sources
  • Table 122. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Mesenchymal Stem Cells Product Picture
  • Figure 2. Global Mesenchymal Stem Cells Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Mesenchymal Stem Cells Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Mesenchymal Stem Cells Report Years Considered
  • Figure 5. Global Mesenchymal Stem Cells Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Mesenchymal Stem Cells Revenue in 2024
  • Figure 7. Mesenchymal Stem Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Umbilical Cord Derived MSC Picture
  • Figure 9. Bone Marrow Derived MSC Picture
  • Figure 10. Placenta Derived MSC Picture
  • Figure 11. Other Picture
  • Figure 12. Global Mesenchymal Stem Cells Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Mesenchymal Stem Cells Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Research
  • Figure 15. Product Picture of Disease Treatment
  • Figure 16. Product Picture of Beauty and Anti-aging
  • Figure 17. Product Picture of Storage
  • Figure 18. Global Mesenchymal Stem Cells Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 19. Global Mesenchymal Stem Cells Sales Value Market Share by Application, 2024 & 2031
  • Figure 20. North America Mesenchymal Stem Cells Sales Value (2020-2031) & (US$ Million)
  • Figure 21. North America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Europe Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Europe Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Asia Pacific Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Asia Pacific Mesenchymal Stem Cells Sales Value by Region (%), 2024 VS 2031
  • Figure 26. South America Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. South America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Middle East & Africa Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Middle East & Africa Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Key Countries/Regions Mesenchymal Stem Cells Sales Value (%), (2020-2031)
  • Figure 31. United States Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. United States Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 33. United States Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 34. Europe Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 36. Europe Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 37. China Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. China Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 39. China Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Japan Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Japan Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Japan Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 43. South Korea Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South Korea Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 45. South Korea Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Southeast Asia Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Southeast Asia Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Southeast Asia Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 49. India Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. India Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 51. India Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Mesenchymal Stem Cells Industrial Chain
  • Figure 53. Mesenchymal Stem Cells Manufacturing Cost Structure
  • Figure 54. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed